Don't Rethink OK'ing Fanapt Patent, Vanda Tells Fed. Circ.
Vanda Pharmaceuticals Inc. has asked the Federal Circuit not to reconsider West-Ward Pharmaceuticals' challenge to a patent covering the schizophrenia drug Fanapt, saying the court rightly found that the medication was...To view the full article, register now.
Already a subscriber? Click here to view full article